CRANBURY, N.J., June 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced the appointment of Ted W. Love, M.D. to its Board of Directors, effective immediately. In addition, Amicus announced that lead Independent Director, Donald J. Hayden, Jr., along with Directors Sol J. Barer, Ph.D., and James N. Topper, M.D., Ph.D, were re-elected at the 2012 Annual Meeting of Stockholders.
John F. Crowley, Chairman and Chief Executive Officer, stated, "On behalf of our Board of Directors, I am pleased to welcome Ted to Amicus. He has overseen development strategies that led to approval and commercial adoption of Rituxan®, Herceptin®, Xolair® and several other innovative treatments. As Amicus advances toward becoming a fully-integrated biopharmaceutical company, Ted's perspectives and experience will be invaluable."
Dr. Love is currently Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. He has overseen Onyx's first new drug application (NDA) submission, as well as the successful launch and execution of two global Phase 3 studies. From 2001 to 2009 Dr. Love served as Chief Executive Officer of Nuvelo, Inc., and served as Chairman and CEO from 2005 to 2009. Prior to Nuvelo, Dr. Love was Senior Vice President of Development at Theravance, Inc. He also held senior management positions in product development and medical affairs for six years at Genentech, where he was responsible for the overall drug development strategy and process that led to marketing approval of six new drugs.
In addition to Amicus, Dr. Love currently serves on the Board of Directors of Affymax, Inc., Bio-Rad Laboratories, Inc., Santarus, Inc. Until recently, he also served as a member of the Independent California Oversight Committee (ICOC) for Stem Cell Research. Dr. Love earned a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.
FOLD-G